Healthcare ratings roundup

• VistaGen Therapeutics (VSTA) initiated with Buy rating and $50 (257% upside) price target by Chardan Capital Markets.
• Axovant Sciences (NASDAQ:AXON) initiated with Sell rating and $10 (48% downside risk) price target by Chardan Capital Markets.
• Omnicell (NASDAQ:OMCL) initiated with Outperform rating and $44 (14% upside) price target by Oppenheimer.
• Juno Therapeutics (NASDAQ:JUNO) initiated with Buy rating and $78 (50% upside) price target by Maxim Group.
• Molina Healthcare (NYSE:MOH) initiated with Buy rating and $80 (18% upside) price target by UBS.
• Pfizer (NYSE:PFE) initiated with Overweight rating and $45 (32% upside) price target by Jefferies.
• Supernus Pharmaceuticals (NASDAQ:SUPN) upgraded to Buy from Hold with an $18 (6% upside) price target by Jefferies.
• Lumenis (NASDAQ:LMNS) downgraded to Market Perform from Outperform by Wells Fargo. Not surprising since XIO Group will acquire at $14 per share.